Share on Facebook Share on Twitter Share on Google Plus Share on Pinterest Share on Linkedin

Monoclonal Antibodies for Treatment of COVID-19

Tampa General Hospital’s Global Emerging Diseases Institute (GEDI) offers monoclonal antibody treatments, which has been shown to help reduce hospitalizations and prevent worsening of COVID-19 symptoms. Treatments are offered at no direct cost to patients.
 

Who is eligible for monoclonal antibody treatment?

Any patient 12 years of age or older who has tested positive for COVID-19. Patients experiencing mild/moderate symptoms - without increased oxygen requirements from symptom onset. Patients who a medical provider deems "high-risk" for their symptoms progressing to a severe level.

Patients must be within seven days of when their symptoms started.

 

Frequently Asked Questions

How does it work?

Monoclonal antibodies have been granted Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for COVID-19 treatment. They are man-made proteins that act like a human antibody in the immune system, defending the body’s cells against the COVID-19 virus. This treatment has been shown to prevent the virus from worsening and spreading.

How is the treatment administered?

The monoclonal antibodies are delivered through a single hour-long infusion treatment. After the procedure, patients are monitored for another hour to ensure there are no side effects and then return home to continue their recovery.
 
 
For more information, contact:
TGH Global Emerging Diseases Institute
GEDIclinic@tgh.org | (813) 844-4715
 
Referral required. Your provider will determine eligibility for this treatment. To refer a patient:
Visit TGH.org/GEDIReferral and complete the GEDI Infusion Center referral form.